Objective To investigate the effect of the FLT3-ITD mutation and the additional chromosomal karyotype on the prognosis of patients with acute promyelocytic leukemia (APL). Methods A total of 112 patients newly diagnosed with APL in The Second Affiliated Hospital of Anhui Medical University from January 2012 to March 2021 were retrospectively analyzed. Clinical and laboratory data were collected. Treatment was selected according to risk stratification. Results 28 APL patients with FLT3-ITD gene mutations, 19 patients with additional chromosome karyotype and 9 early deaths(ED). Complete remission rate(CR) in patients with or without FLT3-ITD mutation was 85.7% and 91.6%(P＞0.05). There was no obvious correlation with ED and high-risk stratification (P＞0.05). The CR rate of patients with or without additional chromosomal karyotype was 78.9% vs 90.3%(P＞0.05), and no obvious correlation with ED and high-risk stratification (P＞0.05). Median follow-up of 68.5(0.1-108.0) month, overall survival was 80.4%, with and without FLT3-ITD mutations was 78.6% and 81.0%, respectively (P＞0.05). Survival rate in patients with or without additional chromosomal karyotypes was 78.9% and 80.6%, respectively (P＞0.05). Conclusion FLT3-ITD mutation and additional chromosomal karyotype had no effect on long-term survival of APL patients.